AVTX — Avalo Therapeutics Cashflow Statement
0.000.00%
- $51.01m
- -$83.53m
- $0.44m
Annual cashflow statement for Avalo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -63.5 | -84.4 | -41.7 | -31.5 | -35.1 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 25.4 | 8.97 | 9.94 | 9.93 | -9.5 |
Discontinued Operations | |||||
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.44 | 2.84 | 4.77 | -9.24 | -4.71 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -40.5 | -70.9 | -26.8 | -30.7 | -49.1 |
Capital Expenditures | -0.063 | -0.113 | -0.095 | -0.158 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 11.2 | 0 | — | 0.025 | 0.356 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 11.1 | -0.113 | -0.095 | -0.133 | 0.356 |
Financing Cash Flow Items | 3.79 | 0 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 44.8 | 107 | -14.7 | 25 | 176 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 15.4 | 35.8 | -41.5 | -5.77 | 127 |